Charlotte Reiche
Dresden, SN 01307, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Soluble TIM-3 and galectin-9 predict survival in gastric and gastroesophageal junction cancer.
Journal: iScience
Published: June 24, 2025
Nectin-4 reduces T cell effector function and is a therapeutic target in pancreatic cancer.
Journal: JCI insight
Published: April 07, 2025
The Value of Blood T Cell Frequencies for Risk Prediction of Postoperative Complications in Pancreatic Cancer Surgery.
Journal: Annals of surgery open : perspectives of surgical history, education, and clinical approaches
Published: July 17, 2024
RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer.
Journal: Nature
Published: April 05, 2024
Serum immune checkpoint profiling identifies soluble CD40 as a biomarker for pancreatic cancer.
Journal: NPJ precision oncology
Published: April 18, 2023
VISTA Ligation Reduces Antitumor T-Cell Activity in Pancreatic Cancer.
Journal: Cancers
Published: March 14, 2023
TIGIT Expression Delineates T-cell Populations with Distinct Functional and Prognostic Impact in Pancreatic Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 28, 2023
IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer.
Journal: Nature
Published: October 25, 2021
Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels.
Journal: Oncogene
Published: August 08, 2019
Showing 1-11 of 11
Last Updated: 09/26/2026